An index of captured practitioner sources, not a completed evidence summary. Unchecked figures and empty sections are omitted. See the library review status.
Source summary generated July 17, 2026; this date does not indicate completed review.
Quotes from three independent practitioners, with their sources. Research context only.
What it is and how it works
From the published literature on Tesofensine; the papers are listed at the end. Research summary, not a recommendation.
What it is
Tesofensine (development code NS2330) is a synthetic small molecule, not a peptide, from the phenyltropane family, developed by the Danish company NeuroSearch. It was first tested in people with Parkinson's and Alzheimer's disease, where it did not improve the diseases but produced unintended weight loss, so development switched to obesity. It is not approved by the FDA or the European Medicines Agency; a partner company applied for approval in Mexico, which had not been granted in the latest company updates found as of 2026-11-06.
How it works
Tesofensine blocks the reuptake of three brain messengers, dopamine, noradrenaline and serotonin, so more of each stays active between nerve cells; this makes it a 'triple monoamine reuptake inhibitor'. In obese rats, its appetite-suppressing effect depended on indirect stimulation of alpha-1 adrenergic and dopamine D1 receptors. In a human metabolism study it strongly increased fullness and reduced hunger and slightly raised energy expenditure at night and fat burning. In mice, it quieted a population of hunger-promoting GABA nerve cells in the lateral hypothalamus.
What it has been studied for
Weight loss in obesity (phase 2 randomized trial)
Appetite and energy expenditure in overweight men (randomized trial)
Early Parkinson's disease (randomized trial, no benefit)
Weight loss observed in Parkinson's and Alzheimer's trials (pooled analysis)
Appetite circuits in the brain (rat and mouse studies)
Strength of the evidence
Human trialsRandomized phase 2 trials in obesity and neurological disease have been published; published phase 3 data were not found, and it is not approved in the US or Europe.
What the literature reports on safety
In trials, tesofensine raised resting heart rate, and the most common side effects were dry mouth, insomnia, nausea, constipation and diarrhoea; higher doses brought more mood and sleep complaints. Blood pressure was not significantly raised at the lower doses in the obesity trial, but rose significantly at the highest dose tested. It is not approved in the United States or Europe, and products sold online under its name are unregulated.
Randomized trial · Astrup A, Madsbad S, et al. · Lancet (2008) · PMID 18950853
In a phase 2 trial in obese adults, tesofensine produced substantially more weight loss than placebo over 24 weeks, raised heart rate, and needed confirmation in phase 3 trials.
Review · Astrup A, Meier DH, et al. · Obesity (2008) · PMID 18356831
A pooled analysis of Parkinson's and Alzheimer's trials found tesofensine caused weight loss without diet changes and raised heart rate without changing blood pressure.
Answers are generated from captured sources and may omit context or contain errors. Check the supporting passages.
What have the teachers said about Tesofensine? Ask what it is, what they say it does, or where they discuss it. Questions about doses or personal use: ask your own clinician.
AI chat. To generate a reply, your question and recent chat history may be processed by Cloudflare Workers AI, Groq, Google Gemini or OpenRouter, depending on availability. Keep personal health details out of the chat and check the cited sources. Research use only; not medical advice.
All content on this page is for research and educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any peptide or hormone protocol. You take responsibility for your own protocol.If your path includes peptides, you buy them yourself from an independent licensed provider through a member co-op; we take nothing. How independent access works.